Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure

Published:2018-10 Issue:5 Volume:11 Page:1155-1159
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Cui ChuanLiang,Zhou Li,Lian Bin,Si Lu,Sheng XiNan,Chi ZhiHong,Kong Yan,Wang Xuan,Tang BiXia,Mao LiLi,Li SiMing,Dai Jie,Yan XieQiao,Bai Xue,Guo Jun

Funder

CSCO-Hengrui Oncology Research Fund

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference17 articles.

1. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib;Sosman;N Engl J Med,2012

2. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

3. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

4. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;Lancet,2014

5. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases;Chi;BMC Cancer,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy for Advanced Malignant Melanoma: Current Research Status and Progress;Journal of Clinical Personalized Medicine;2024

2. Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies;Cancers;2022-08-03

3. Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review;BMC Cancer;2022-04-07

4. Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma;The Oncologist;2022-03-28

5. Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy;Melanoma Research;2022-02-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3